Contact Us Back to the Newsroom ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025 Presenting on Wednesday, December 3, 2025 Members of the ClearPoint Neuro management team will be onsite and available for in-person investor meetings who are registered to attend the various conferences. Topic:Â Conferences SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene t ...

Group 1: Market Overview - U.S. stock futures showed mixed results, with Nasdaq futures gaining over 100 points [1] Group 2: Kimberly-Clark Corporation - Kimberly-Clark Corporation announced the acquisition of Kenvue in a cash and stock transaction valued at approximately $48.7 billion [1] - Following the announcement, Kimberly-Clark shares fell sharply by 13.6% to $103.50 in pre-market trading [1] Group 3: Other Notable Stock Movements - uniQure N.V. shares dropped 65.3% to $23.40 after receiving FDA feedback regarding its investigational gene therapy AMT-130 [3] - ClearPoint Neuro, Inc. saw a decline of 40.5% to $13.77 in pre-market trading [3] - ALPS Group Inc fell 40.2% to $1.53 following the announcement of a public offering [3] - Biohaven Ltd. shares decreased by 27.4% to $12.48 [3] - Alvotech experienced a 24.1% drop to $5.80 after receiving an FDA Complete Response Letter for its AVT05 biosimilar application [3] - Replimune Group, Inc. dipped 16.7% to $8.10, despite an upgrade from BMO Capital [3] - Praxis Precision Medicines, Inc. declined 9.1% to $180.70 [3] - Vertex, Inc. fell 6.1% to $21.50 after lowering its FY2025 sales guidance [3]

Group 1 - U.S. stock futures showed mixed results, with Nasdaq futures gaining over 100 points [1] - Kimberly-Clark Corporation announced the acquisition of Kenvue for approximately $48.7 billion, leading to a 13.6% drop in its shares to $103.50 in pre-market trading [1] Group 2 - uniQure N.V. experienced a significant decline of 65.3% to $23.40 after receiving FDA feedback regarding its investigational gene therapy AMT-130 [3] - ClearPoint Neuro, Inc. shares fell 40.5% to $13.77, while ALPS Group Inc dropped 40.2% to $1.53 following the announcement of a public offering [3] - Biohaven Ltd. shares decreased by 27.4% to $12.48, and Alvotech fell 24.1% to $5.80 after receiving an FDA Complete Response Letter [3] - Replimune Group, Inc. saw a 16.7% dip to $8.10, despite an upgrade from BMO Capital analyst [3] - Praxis Precision Medicines, Inc. declined 9.1% to $180.70, and Vertex, Inc. fell 6.1% to $21.50 after lowering its FY2025 sales guidance [3]

(NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy. The study cohort comprised fourteen patients ages 18-80years with primary and recurrent glioblastoma and grade 4 astrocytoma, tumors which are among the most challenging to t ...

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced several expanded regulatory approvals for product use in Canada, Hong Kong, and Taiwan. ...

Key Takeaways CLPT introduced a robotic system integrating its neuro-navigation software with KUKA's arm.CLPT's platform targets biopharma partners launching complex brain-delivered cell and gene therapies.Collaborations and software focus reduce risk, speed timelines, and position CLPT for long-term growth.ClearPoint Neuro (CLPT) recently unveiled the development of its proprietary Robotic Neuro-Navigation System, a move that positions the company to contribute to robotics, neurosurgery, and advanced drug ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Xcel Brands, Inc. (XELB) increased by 48% to $2.57 [3] - Astrotech Corporation (ASTC) rose by 21% to $5.85 [3] - Rumble Inc. (RUM) saw a 13% increase to $8.36 [3] - ClearPoint Neuro, Inc. (CLPT) gained 9% reaching $27.38 [3] - USA Rare Earth, Inc. (USAR) also increased by 9% to $24.92 [3] - Q/C Technologies, Inc. (QCLS) rose by 8% to $5.51 [3] - Lazydays Holdings, Inc. (GORV) increased by 8% to $2.61 [3] - K Wave Media Ltd. (KWM) saw a 7% rise to $2.78 [3] - Galectin Therapeutics Inc. (GALT) increased by 6% to $4.53 [3] - Wrap Technologies, Inc. (WRAP) rose by 6% to $2.86 [3] Premarket Losers - Black Titan Corporation Ordinary Shares (BTTC) decreased by 29% to $16.80 [4] - Masonglory Limited (MSGY) fell by 14% to $2.54 [4] - Aspire Biopharma Holdings, Inc. (ASBP) declined by 12% to $0.37 [4] - Urban One, Inc. (UONE) saw an 11% drop to $1.15 [4] - Reitar Logtech Holdings Limited (RITR) decreased by 7% to $2.74 [4] - Iveda Solutions, Inc. (IVDA) fell by 7% to $1.88 [4] - Erayak Power Solution Group Inc. (RAYA) decreased by 6% to $4.93 [4] - Megan Holdings Limited (MGN) saw a 6% drop to $3.32 [4] - Werewolf Therapeutics, Inc. (HOWL) declined by 5% to $1.81 [4] - SOS Limited (SOS) decreased by 4% to $2.04 [4]

Group 1 - ClearPoint Neuro's share price increased significantly due to positive data from uniQure regarding Huntington's disease treatment [1] - The financial impact of uniQure's AMT-130 is expected to be substantial, but the data serves as confirmatory evidence of ClearPoint's potential [1] - Narweena, an asset manager led by Richard Durant, focuses on identifying market dislocations caused by misinterpretations of long-term business prospects [1] Group 2 - Narweena aims to achieve excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with high entry barriers [1] - The research process at Narweena emphasizes company and industry fundamentals to uncover unique insights [1] - The investment strategy is influenced by demographic trends, particularly an aging population and low population growth, which may create new investment opportunities [1] Group 3 - Many industries are anticipated to experience stagnation or secular decline, potentially improving business performance due to reduced competition [1] - Conversely, some businesses may face rising costs and diseconomies of scale [1] - The economic landscape is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments [1] Group 4 - A significant amount of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia over time [1] - Richard Durant holds degrees in engineering and finance, along with an MBA, and has passed the CFA exams, indicating a strong educational background [1]

ClearPoint Neuro's (NASDAQ: CLPT ) share price recently surged on the back of uniQure's ( QURE ) extremely strong Huntington's data. While the financial impact of AMT-130 should be meaningful, the data is more important as confirmatory evidence of the strength of ClearPoint’sRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can b ...

Core Insights - ClearPoint Neuro, Inc. has announced the development of a proprietary Robotic Neuro-Navigation System to enhance its navigation software capabilities [1] - This new product will support minimally invasive cranial surgical procedures, including cell and gene therapy infusions, laser catheter placements, biopsy workflows, and deep brain stimulation [1] Company Developments - The Robotic Neuro-Navigation System will operate the KUKA LBR Med Robotic Arm, providing added flexibility for commercial launches in the field of cell and gene therapy [1] - The introduction of this technology positions ClearPoint Neuro as a key player in the evolving landscape of neurosurgical procedures [1]